FOXP3 and invasive breast carcinoma: There were no statistically significant differences in the score of FOXP3 + regulatory T lymphocytes between 30 DCIS patients with further recurrence and its invasive breast cancer (median 0% vs.1%, respectively, p = 0.439), but a modest increase in the score of those cells after invasion was observed.